BRCA1, a tumor suppressor protein implicated in hereditary forms of breast and ovarian cancer, is transcriptionally regulated in a proliferation-dependent manner. In this study, we demonstrate a substantial role for proteolysis in regulating the BRCA1 steady-state protein level in several cell lines. N-acetyl-leu-leunorleucinal (ALLN), an inhibitor of the proteasome, calpain, and cathepsins, caused BRCA1 protein to accumulate in the nucleus of several human breast, prostate, and melanoma cell lines which express low or undetectable basal levels of BRCA1 protein, but not in cells with high basal expression of BRCA1. Protease inhibition did not increase BRCA1 synthesis, nor change its mRNA level, but it dramatically prolonged the protein's half-life. In contrast to ALLN, lactacystin and PS341, two speci®c proteasome inhibitors, as well as calpastatin peptide and PD150606, two selective calpain inhibitors, had no eect on BRCA1 stability, whereas ALLM, an eective calpain and cathepsin inhibitor but weak proteasome inhibitor, did stimulate accumulation of BRCA1. Moreover, three inhibitors of acidic cysteine proteases, chloroquine, ammonium chloride and ba®lo-mycin, were as eective as ALLN. These results demonstrate that degradation by a cathepsin-like protease in ®ne balance with BRCA1 transcription is responsible for maintaining the low steady-state level of BRCA1 protein seen in many cancer cells.
Introduction
BRCA1 is a tumor suppressor gene whose inactivation is associated with a high incidence of familial breast and ovarian cancer (see Blackwood and Weber, 1998) , and loss of BRCA1 function also has been implicated in the development of prostate cancer (Bishop and Kiemeney, 1997) . BRCA1 over-expression can inhibit cell proliferation by transactivating p21 WAF1/CIP1 in both a p53-dependent and a p53-independent manner (Thompson et al., 1995; Somasundaram et al., 1997; Ouchi et al., 1998; Zhang et al., 1998) . Paradoxically, loss of BRCA1 in an embryonic setting activates a growth arrest pathway that is dependent on p53 and p21 WAF1/CIP1 (Brugarolas and Jacks, 1997) . In addition, high expression of BRCA1 mRNA is correlated with increased proliferation (Gudas et al., 1996) . It has been shown that BRCA1 mRNA is highly expressed in late G1 phase of the cell cycle, whereas conditions that lead to cell cycle exit down-regulate the BRCA1 mRNA (Gudas et al., 1995 (Gudas et al., , 1996 Jin et al., 1997) . However, despite the cell cycle dependence of BRCA1 mRNA expression, BRCA1 protein level does not change during the cell cycle (Aprelikova et al., 1996) .
The mRNA of another tumor suppressor gene, p53, also¯uctuates throughout the cell cycle (Reich and Levine, 1984; Mercer and Baserga, 1985) , however, its expression in response to physiologic stimuli is regulated post-translationally (Kastan et al., 1991; Nelson and Kastan, 1994; An et al., 1998) . Although BRCA1 mRNA and protein levels are fairly well correlated in vitro, we noticed that, across cell lines, BRCA1 protein level tended to vary much more widely than the level of its mRNA. These observations led us to examine more closely the role of post-translational events in regulating BRCA1 expression. We report here that inhibition of an acidic cysteine protease activity caused rapid nuclear accumulation of BRCA1 protein, secondary to protein stabilization, in several breast, prostate and melanoma-derived cell lines in which BRCA1 steadystate expression is very low. In contrast to wild type p53, nuclear accumulation of BRCA1 was not observed following treatment with leptomycin B, an inhibitor of nuclear export. Protease inhibition did not aect the BRCA1 protein level in cell lines with high steady-state expression.
Results

Accumulation of BRCA1 protein following inhibition of proteolysis
DU145 is a cell line that expresses low steady-state levels of BRCA1. BRCA1 protein was weakly visible by immuno¯uorescence as a punctate staining pattern in the nuclei (identi®ed by DAPI staining, see Materials and methods) of untreated DU145 cells (Figure 1, top panels) . In contrast, 6 h after the cells were exposed to the protease inhibitor ALLN (100 mM), the nuclear signal for BRCA1 was greatly enhanced (Figure 1 , bottom panels). Even after ALLN treatment, BRCA1 expression appeared restricted to the nucleus.
In order to determine how widespread this phenomenon was, we next measured the level of BRCA1 protein by Western blot before and after ALLN treatment in several breast, prostate and melanoma cell lines (Figures 2a and 3 ). In agreement with the immuno¯uorescence data, BRCA1 protein was barely detectable in untreated cells and markedly elevated in cells exposed for 4 ± 6 h to ALLN in DU145 (prostate carcinoma), MCF10 (non-tumorigenic breast epithelium), SKBR3 (breast carcinoma), MEL1011 (melanoma), MEL1241 (melanoma), and MEL928 (melanoma). In contrast, PC3M (prostate carcinoma), MCF7 (breast carcinoma), MDA-MB231 (breast carcinoma) and MDA-MB468 (breast carcinoma) cells expressed high basal levels of BRCA1 protein but did not respond further to ALLN, suggesting that the high basal levels of BRCA1 observed in these cells may be partially due to retarded degradation of the protein. ALLN activity was demonstrated by its ability to cause accumulation of wild type p53 in MCF10 cells ( Figure  4c ) and MCF7 cells (data not shown). Immunoblots were re-probed for topoisomerase I (Figures 2a and 3b ) or mutant p53 (Figure 3c, DU145 and SKBR3) to demonstrate equal protein loading. In all cell lines examined, BRCA1 protein was localized almost exclusively to the nucleus both before and after ALLN treatment (Figures 1 and 2c , and data not shown). In all subsequent experiments, BRCA1 protein was assayed from nuclear extracts.
ALLN does not aect BRCA1 mRNA level, or the rate of BRCA1 protein synthesis
In order to determine whether ALLN induced BRCA1 accumulation by altering its synthesis, we ®rst measured BRCA1 mRNA levels in several ALLNresponsive and non-responsive cell lines (Figure 2b ).
MCF7 expressed a relatively high amount of BRCA1 mRNA, whereas DU145 and MCF10 expressed lower levels of BRCA1 mRNA, in agreement with previously published data (Gudas et al., 1996) . However, in no case did ALLN signi®cantly aect BRCA1 mRNA expression. These data were con®rmed in SKBR3 and PC3M cells (data not shown).
Next, we pre-incubated DU145 cells with ALLN for 4 h and then labeled cells with 35 S-methionine for 20 min. Such a brief labeling protocol allows for detection of alterations in BRCA1 synthesis which are independent of protein half-life. Following immunoprecipitation with anti-BRCA1 antibody, we determined the amount of BRCA1 protein synthesized de novo in the presence and absence of ALLN ( Figure  2d ). The data clearly show that ALLN exposure did not signi®cantly aect the synthesis of BRCA1 protein. Similar results were seen with SKBR3 cells (data not shown).
BRCA1 protein accumulated after ALLN has an increased half-life
Accumulation of BRCA1 protein without a change in either its RNA level or rate of synthesis strongly suggests that ALLN causes BRCA1 stabilization. In order to determine the eects of this protease inhibitor on the approximate stability of BRCA1 protein, DU145 cells were treated with ALLN for 4 h, and then cycloheximide (CHX, 100 mg/ml) was added to block protein synthesis. At various times after addition of CHX, BRCA1 levels were monitored by Western blot. The approximate half-life of BRCA1 protein in untreated DU145 cells was found to be about 2 h, but this increased to greater than 6 h (the longest time Figure 1 ALLN-dependent nuclear accumulation of BRCA1 protein. DU145 cells growing on coverslips were treated with 100 mM ALLN for 6 h and BRCA1 protein was visualized by immuno¯uorescence. The DNA-intercalating dye DAPI was used to identify cell nuclei point examined) in cells exposed to ALLN (Figure 2e ). In fact, extrapolation of the decay curve obtained from the ALLN-treated cells in Figure 2e yields an estimated half-life of greater than 24 h. Figure 2 ALLN-dependent accumulation of BRCA1 protein due to protein stabilization occurs in cells with low basal levels of BRCA1. (a) BRCA1 protein level in nuclear extracts of MCF7, DU145 and MCF10 cells was monitored by Western blotting following a 6-h exposure to ALLN (100 mM). Blots were re-probed for topoisomerase I to con®rm equal protein loading. (b) BRCA1 mRNA was analysed from a duplicate experiment to that described in part (a). Ethidium staining of the gel (lower panel) con®rmed equal RNA loading. (c) BRCA1 protein was analysed by Western blot from nuclear and cytoplasmic extracts prepared from DU145 cells treated as in part (a). Blots were re-probed for either mutated p53 or actin to con®rm equal protein loading of nuclear and cytoplasmic fractions, respectively. (d) To determine the eect of ALLN on BRCA1 synthesis, DU145 cells, treated as in part (a), were pulsed with [ 35 S]methionine for 20 min, and BRCA1 was then immunoprecipitated from a nuclear extract and subjected to SDS ± PAGE. Equal amounts of protein were loaded in each lane. (e) The eect of ALLN on BRCA1 half-life was determined by treating DU145 cells as in part (a), and then detecting BRCA1 protein by Western blot at various times after addition of cycloheximide (CHX, 100 mg/ml). The immunoblot (shown in inset) was quanti®ed with NIH Image software after being scanned into a Macintosh 9500 computer. The optical densities of BRCA1-speci®c bands were plotted on a semi-log graph using Cricket Graph software and best-®t lines were drawn through each set of data. Closed circles represent untreated cells; open circles represent ALLN-treated cells Acidic proteases, but not the proteasome or calpain, degrade BRCA1 ALLN inhibits both the proteasome and calpain, as well as the acidic cathepsins found in lysosomes (Rock et al., 1994; Paoletti et al., 1997) . In order to determine which proteolytic pathway was responsible for BRCA1 degradation in cell lines with low basal levels of the protein, we tested in several cell lines the potency of a panel of protease inhibitors with overlapping activities (Figures 3c and 4a,b) . ALLM, although a less potent inhibitor of the proteasome, is an active cathepsin inhibitor (Inoue et al., 1991) , while lactacystin and PS341 are both highly selective proteasome inhibitors (Fenteany and Schreiber, 1999; Grisham et al., 1999) . Although ALLM was as ecient as ALLN in causing accumulation of BRCA1, both lactacystin and PS341 were ineective, thus eliminating the proteasome as the BRCA1 protease. As expected, mutant p53 is expressed at high basal levels in DU145 and SKBR3 due to protein stabilization, and it did not respond to proteasome inhibition in either cell line (Figure 3c ). In contrast, wild type p53, which is proteasome-sensitive Schener, 1998) , was increased in MCF-7 cells exposed to the speci®c proteasome inhibitor PS-341, but not in cells treated with ammonium chloride, an inhibitor of acidic proteases (Figure 3c ). Additional evidence of PS-341 and lactacystin activity was obtained by demonstrating their ability to increase wild type p53 in MCF10 cells at concentrations and exposure times which failed to aect BRCA1 ( Figure  4b) .
In order to distinguish between the calpain and cathepsin inhibitory activities of both ALLN and ALLM, we examined the activity of two selective calpain inhibitors, cell-permeable calpastatin peptide and the non-peptide calpain inhibitor PD150606 Carafoli and Molinari, 1998) . Neither agent proved eective in stimulating accumulation of BRCA1, making calpain-dependent BRCA1 degradation unlikely. In contrast, three agents which inhibit acidic cathepsin proteases ± ammonium chloride, chloroquine, and ba®lomycin ± all strongly stimulated BRCA1 accumulation in cells whose BRCA1 protein was sensitive to ALLN (Figures 3c and 4a, b) . Ammonium chloride failed to aect BRCA1 level in MCF7 cells, in which BRCA1 protein was also Figure 2a . Where BRCA1 was altered by treatment, blots were re-probed for topoisomerase I to con®rm equal protein loading. (c) BRCA1 protein was monitored by Western blot in nuclear extracts prepared from DU145, SKBR3 and MCF7 cells exposed to a panel of protease inhibitors of diering speci®cities. Cells were exposed to all inhibitors for 6 h. Blots were reprobed for mutated p53 (DU145 and SKBR3) to con®rm equal protein loading. Induction of wild type p53 in MCF7 is a positive control for PS-341 activity resistant to ALLN (Figures 2a and 3c) . Accumulation of wild type p53, previously shown to be sensitive to calpain as well as proteasome inhibition (Gonen et al., 1997; Kubbutat and Vousden, 1997; Pariat et al., 1997; Zhang et al., 1997) , was demonstrated in MCF10 cells at the concentrations/incubation times used of the calpain inhibitors calpastatin peptide and PD150606 (Figure 4b ).
Figure 4 BRCA1 protein accumulates after inhibition of acidic cysteine proteases, but not after speci®c inhibition of either the proteasome or calpain proteases, or after inhibition of nuclear export. (a), (b), BRCA1 protein was monitored by Western blot in nuclear extracts prepared from DU145 and MCF10 cells treated with a panel of protease inhibitors as in Figure 2a . Equal protein loading was con®rmed by re-probing for topoisomerase I. Wild type p53 protein was also monitored in MCF10 cells to demonstrate activities of calpain protease and proteasome inhibitors. (c) MCF10 cells were treated with either leptomycin B (LMB, 10 ng/ml), or ALLN (100 mM) for 6 and 24 h. The BRCA1 content of nuclear extracts was analysed by Western blot. Blots were re-probed for wild type p53 to demonstrate activity of leptomycin B. (d) DU145 and SKBR3 cells were treated with actinomycin D (Act D, 2 mg/ ml), ALLN (100 mM), or a combination of both drugs for 6 h, and then BRCA1 protein was analysed from nuclear extracts by Western blot Inhibition of CRM1-mediated nuclear export fails to cause accumulation of BRCA1
Crm-1 is an evolutionarily conserved nuclear protein which serves as an essential mediator of nuclear export signal (NES)-dependent transport of proteins from nucleus to cytoplasm (Fukuda et al., 1997) . Leptomycin B has recently been described as a natural product which binds speci®cally to Crm-1 and inhibits the nuclear export of a wide variety of proteins (Nishi et al., 1994; Fornerod et al., 1997; Kudo et al., 1998) , including wild type p53 (Freedman and Levine, 1998; Lain et al., 1999; Stommel et al., 1999) . Because inhibition of an acidic protease led to nuclear accumulation of BRCA1, we reasoned that, if BRCA1 degradation required transport to the cytoplasm, leptomycin B might cause nuclear accumulation of BRCA1 in the absence of protease inhibition. Thus, we treated MCF10 cells for 6 and 24 h with either leptomycin B (LMB, 10 ng/ml), or ALLN (Figure 4c ). To our surprise, leptomycin B treatment failed to cause nuclear accumulation of BRCA1, although the protein accumulated in response to ALLN. The activity of leptomycin in MCF10 cells was demonstrated by its ability to cause nuclear accumulation of wild type p53 (Figure 4c ). These results were con®rmed by immunouorescence observations made in intact cells (data not shown).
ALLN abrogates actinomycin D-induced BRCA1 down-regulation
In cells with low basal levels of BRCA1, protein expression is still dependent on transcription. Thus, a 6-h exposure of DU145 and SKBR3 cells to actinomycin D (2 mg/ml) down-regulated BRCA1 protein to undetectable levels ( Figure 4d ). However, co-incubation of these cells with actinomycin D and ALLN completely abrogated actinomycin D-induced BRCA1 down-regulation. Incubation with ALLN alone is shown for comparison. These data demonstrate that in DU145 and SKBR3 cells, the low steadystate level of BRCA1 protein results from a ®ne regulatory balance between BRCA1 transcription and proteolytic degradation.
Discussion
We examined BRCA1 expression in ten breast, melanoma and prostate cancer cell lines, and we found that these cell lines could be grouped into two categories based on their steady-state level of BRCA1 protein. In six of ten cell lines, BRCA1 protein was barely detectable, while in the remaining four cell lines BRCA1 protein was expressed at high levels. In the low-expressing cells, BRCA1 level was regulated by protein degradation as well as by transcription. Thus, incubation with actinomycin D for as little as 6 h was sucient to deplete BRCA1 protein from DU145 and SKBR3 cells, but this depletion was blocked by coincubation with the protease inhibitor ALLN. BRCA1 accumulation occurred in cell nuclei following inhibition of proteolysis by ALLN, but this was only observed in cells with low basal levels of BRCA1. In such cells, ALLN treatment increased BRCA1 protein half-life, but it did not signi®cantly alter either BRCA1 synthesis or mRNA level.
Although ALLN is commonly used as a proteasome or calpain inhibitor, its eect on BRCA1 appears to be mediated by its ability to inhibit another class of cysteine proteases, the cathepsins, which function optimally at an acidic pH and are generally sequestered within lysosomes. Thus, neither the speci®c proteasome inhibitors lactacystin and PS341, nor the speci®c calpain inhibitors calpastatin peptide and PD150606 were able to mimic the eects of ALLN, while three agents which prevent intracellular acidification and which are considered to be speci®c inhibitors of acidic proteases ± chloroquine, ammonium chloride, and ba®lomycin ± all caused nuclear accumulation of BRCA1.
In cells sensitive to ALLN and the cathepsin inhibitors, the approximate half-life of BRCA1 in untreated cells was 2 h. It is unusual for a lysosomal enzyme, and not the proteasome, to be responsible for the proteolysis of such a short-lived protein, although other transcription factors have been reported to be substrates for cathepsins or cathepsin-like proteases (Aniento et al., 1996; Nagaya et al., 1998) . Two recent reports have described both the nuclear and cytosolic localization of a novel cathepsin-like protease, termed SPase, which has as substrates the retinoblastoma susceptibility gene product, Rb, and the transcription factor Sp1 (Nishinaka et al., 1997; Fu et al., 1998) . Similarly, a plausible interpretation of our data suggests that a nuclear-localized cathepsin-like acidic protease mediates the degradation of BRCA1 in the low-expressing cells. This hypothesis is supported by the observation that leptomycin B, a speci®c inhibitor of NES-dependent nuclear export, does not mimic the eect of ALLN, which it would be expected to do if BRCA1 degradation depended on cytosolic proteolysis. For example, both leptomycin B and ALLN treatment cause a robust accumulation of nuclear p53 (see Figure  4c ), which must be transported to the cytosol to undergo proteasomal degradation (Freedman and Levine, 1998; Lain et al., 1999; Stommel et al., 1999) . However, a recent report that factors distinct from Crm-1 may mediate the nuclear export of at least one NES-containing protein, protein kinase inhibitor, raises a caveat to this hypothesis (Holaska and Paschal, 1998) . Although we have no evidence that BRCA1 degradation requires nuclear export, if BRCA1 degradation does occur in the cytoplasm, our data would suggest that most of the newly synthesized protein must normally be degraded by lysosomal proteases prior to nuclear import. In the absence of lysosomal degradation (i.e., in the presence of ALLN), nuclear accumulation of BRCA1 would thus occur unimpeded by competing proteolysis.
Is the normal BRCA1 that protein which exists at low steady-state levels and is sensitive to ALLN, or is it the BRCA1 that is resistant to ALLN and exists at high steady-state levels? By analogy with another tumor suppressor, p53, both possibilities exist. Wild type p53 protein is normally rapidly degraded, while mutated p53 is stabilized and accumulates to high levels, in part to compensate the loss of transcriptional function (Blagosklonny, 1997) . One can envision that stable/over-expressed BRCA1 may be functionally impaired. Interestingly, cell lines expressing a high level of ALLN-insensitive BRCA1 protein also contained greater amounts of BRCA1 mRNA than did the low-expressing cell lines. Although this might occur coincidently, elevated levels of BRCA1 mRNA might re¯ect the cell's attempt to compensate for loss of BRCA1 function. In support of this hypothesis, although MCF7 cells express a high steady-state level of endogenous BRCA1 protein (see Figure 2) , it has been shown that expression of an exogenous BRCA1 gene in these cells causes growth inhibition (Holt et al., 1996) . However, functional impairment of BRCA1 is dicult to identify, because its critical role in the cell remains nebulous. In fact, BRCA1 appears to possess multiple activities, including modulation of p53 activity (Ouchi et al., 1998; Zhang et al., 1998; Chai et al., 1999) , independent transactivating activity (Chapman and Verma, 1996; Monteiro et al., 1996; Somasundaram et al., 1997) , a role in DNA damage sensing/repair (Scully et al., 1997; Brugarolas and Jacks, 1997; Andres et al., 1998) and, most recently described, transcriptional repression of estrogen-dependent signaling (Fan et al., 1999) .
Alternatively, the very low steady-state level of BRCA1 observed in six of ten cell lines in this study might represent inappropriate inactivation of the protein. In this case, an analogy can be drawn to E6-induced degradation of wild type p53, a mechanism by which p53 is inactivated in some cases of cervical carcinoma (Schener et al., 1990) . Neither model need be mutually exclusive, and the method of BRCA1 inactivation may depend on cellular background. Nevertheless, our ®ndings implicate the signi®cant involvement of a nuclear acidic protease in the regulation of BRCA1 expression in a number of cancer cell lines which are characterized by low steady-state expression of this protein.
Materials and methods
Cell culture
The human cancer cell lines used in this study include the breast-derived lines MCF7, MCF10, SKBR3, MDA-MB231, MDA-MB468; the prostate-derived DU145 and PC3M; and the melanoma cell lines MEL928, MEL1011, and MEL1241. Cell culture conditions were as previously described (Blagosklonny et al., 1995; Whitesell et al., 1997) .
Materials
Actinomycin D was obtained from the Drug Synthesis and Chemistry Branch of the National Cancer Institute, prepared as a stock solution in water, and used at a ®nal concentration of 2 mg/ml. Lactacystin (LC), a speci®c proteasome inhibitor, was obtained from Calbiochem (La Jolla, CA, USA), prepared as a 2 mM stock solution in distilled water, and was used at 10 mM ®nal concentration. N-acetyl-leu-leunorleucinal (ALLN) and N-acetyl-leu-leu-normethional (ALLM) were purchased from Sigma Chemical Co. (St Louis, MO, USA), prepared in DMSO and used at 100 mM ®nal concentration. Ammonium chloride, chloroquine and ba®lomycin were purchased from Sigma and prepared in distilled water before use at ®nal concentrations of 2.5 mM, 100 mM, and 100 nM, respectively. Cell permeable calpastatin peptide and the non-peptide calpain inhibitor PD150606 were purchased from Calbiochem and were used at 0.1 ± 20 mM ®nal concentration. The proteasome inhibitor PS341 was obtained as a kind gift from Dr Peter Elliott, Proscript, Inc.
(Cambridge, MA, USA) and it was used at a ®nal concentration of 10 mM. Cycloheximide was purchased from Sigma and used at a ®nal concentration of 100 mg/ml. Leptomycin B was obtained from Dr Minoru Yoshida (University of Tokyo), prepared as a stock solution in ethanol and used at a ®nal concentration of 10 ng/ml.
Preparation of nuclear extracts
High-salt nuclear extracts were prepared using a modi®cation of the method of Andrews and Faller (1991) . Brie¯y, cells were washed once with ice-cold PBS and then scraped into cold PBS. After centrifugation, cells were resuspended in icecold swelling buer (10 mM HEPES-KOH, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, 0.5 mM PMSF) and allowed to swell for 15 min on ice. Lysis was accomplished by adding 1/16th volume of 10% NP40 and vortexing vigorously for 10 s. After centrifugation in the cold for 2 min, the supernatant was discarded and the pellet was resuspended in cold extraction buer (20 mM HEPES-KOH, pH 7.9, 25% glycerol, 400 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM dithiothreitol, 1 mM PMSF), and rocked for 15 min on ice. Cellular debris was removed by centrifugation for 2 min at 48C, and the supernatant fraction, representing a high-salt nuclear extract, was stored at 7708C until use. In some experiments, the supernatant obtained after NP40 lysis was saved and used to measure cytosolic BRCA1 content. Total protein concentration of each fraction was determined with the BCA-protein reagent, using bovine serum albumin as standard (Pierce, Rockford, IL, USA). Depending on the experiment, 80 ± 100 mg of protein were used for Western blotting.
Immunoblotting
Murine monoclonal anti-BRCA1 antibody (Ab-1, Oncogene Research Products, Cambridge, MA, USA) was used for immunoblotting. Equal protein loading was con®rmed by reprobing blots with antibodies to p53 (Ab-2, Oncogene Research Products), topoisomerase I (Ab-1, Oncogene Research Products), or actin (Ab-1, Oncogene Research Products). Blots were developed by incubation with a peroxidase-labeled secondary antibody followed by application of a chemiluminescent peroxidase substrate (Dupont/ NEN) as described previously (Blagosklonny et al., 1995) .
S-methionine-labeling and immunoprecipitation
Cells were labeled for 20 min with 35 S-methionine/cysteine (Translabel, ICN Biomedical, Costa Mesa, CA, USA, 100 mCi/ml), washed in PBS and lysed as above. BRCA1 was immunoprecipitated from 200 mg nuclear extract using an anti-human BRCA1 rabbit polyclonal antibody (D-20; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) as previously described . Immunoprecipitates were resolved by 7.5% SDS ± PAGE. Gels were ®xed, enhanced (Enlightening TM , Dupont/NEN, Boston, MA, USA), dried and exposed to Kodak XAR-5 ®lm. BRCA1-speci®c bands were quanti®ed by densitometric scanning/ image analysis.
BRCA1 indirect immuno¯uorescence
DU145 cells were grown on sterile coverslips, ®xed with 3.7% formaldehyde in PBS for 10 min, and permeabilized with 0.2% Triton X-100 for 10 min at room temperature. Nonspeci®c binding sites were blocked by incubating the cells with 1% bovine serum albumin in PBS for 1 h at 48C. Mouse monoclonal anti-BRCA1 antibody (Ab-1, Oncogene Research Products) was added to the coverslip and incubated for 1 h at 48C. Coverslips were washed twice for 2 min with PBS, and incubated at 48C for 1 h with Cy3-conjugated goat anti-mouse immunoglobulin (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA). After incubation, the coverslips were washed with PBS, rinsed quickly with water, air-dried, mounted using SlowFade (Molecular Probes, Eugene, OR, USA), and imaged using a Zeiss Axiophot microscope interfaced with a CCD camera (Optronics Engineering, Goleta, CA, USA).
Northern blotting
Total RNA was isolated using RNAzol B (Cinna/Biotek), following manufacturer's instructions. Twenty micrograms of total RNA were electrophoresed through a 1% agarose/ formaldehyde gel, transferred to nitrocellulose and hybridized in Express Hyb solution (CLONTECH) according to the manufacturer's recommendation. The cDNA for the BRCA1 gene (obtained from Dr B Weber, University of Pennsylvania) was radiolabeled with 32 P-dCTP using an RTS RadPrime DNA labeling system (GIBCO BRL). The blot was hybridized for 1 h with radiolabeled probe (1.5610 6 c.p.m./ ml), washed as previously described (Melillo et al., 1995) , and autoradiographed.
